Our data extend the findings of recent studies demonstrating that TRPML1 agonists correct pathogen-induced lysosomal vacuolization by Helicobacter pylori (74), providing a specific point of entry for the development of host-directed TB therapy through lysosome activation. The gene discussed is MCOLN1; the disease is tuberculosis.